Awake Craniotomy: Pengalaman dengan Dexmedetomidin

Dewi Yulianti Bisri, Tatang Bisri

Abstract


Awake craniotomy (AC) menggunakan anestesi lokal dan sedasi termonitor untuk mengambil tumor intrakranial yang mengenai eloquent cortex merupakan teknik yang telah diterima. Teknik ini memungkinkan dilakukan pemetaan intraoperatif yang memfasilitasi reseksi tumor secara radikal dan meminimalkan morbiditas dengan mempertahankan jaringan yang berfungsi. Kebutuhan pemetaan cortex adalah untuk menggambarkan fungsi otak, seperti bicara, sensoris, dan motoris dengan tujuan untuk mempertahankannya selama dilakukan reseksi. Obat yang diberikan harus dapat memberikan level sedasi dan analgesi yang adekuat untuk mengangkat tulang, tapi tidak mempengaruhi testing fungsonal dan elektrokortikografi. Prosedur sama dengan kraniotomi standar, tapi dengan satu perbedaan-pasien sadar penuh selama pemetaan korteks dan reseksi tumor. Pasien mampu bicara dan bergerak normal. Pasien tidak selalu bangun selama pembedahan, tapi tidur dalam 1–2 jam pertama dan atau setelah reseksi tumor. Tidak ada rasa sakit selama sadar. Sasaran anestesi adalah pasien nyaman, mampu tidak bergerak selama pembedahan, sadar dan kooperatif saat pemetaan korteks yang dapat dicapai dengan: 1) persiapan pasien yang adekuat, 2) lingkungan nyaman, 3) pemberian sedatif analgesik yang tepat, 4) selalu berkomunikasi dengan pasien, dan 5) cepat diterapi bila ada komplikasi. Dexmedetomidine adalah suatu a–2 adrenoceptor agonist spesifik dengan efek sedatif, analgesik, anesthetic sparring effect, bangun bila distimulasi, efek proteksi otak, tidak adiksi, tidak menekan respirasi. Pasien yang diberikan dexmedetomidin bisa tersedasi dan nyaman tapi mudah dibangunkan dan mentoleransi AC yang berlangsung lama.

 

Awake Craniotomy: Experience with Dexmedetomidine

Awake craniotomy (AC) using local anesthesia and monitored sedation in intracranial tumor removal involving eloquent cortex has been considered as an acceptable technique. It allows intraoperative mapping that facilitates radical tumor resection while minimizing morbidity by preserving functional tissue. Anesthesia for intracranial procedure requiring patient cooperation present a challange to the anesthesiologist. The need for cortex mapping is to describe brain function, such as verbal, sensoric and motoric aiming for maintain its function during resection. The administered drugs should provide an adequate level of sedation and analgesia for bone flap removal, but must not interfere with functional testing and electrocorticography. The procedure is very similar to a standard craniotomy, but with one difference-the patient is fully awake during cortical mapping and tumor resection. Patient is able to talk and move normally. The patient should not awake during surgery, but is in deep sleep for the first 1-2 hours and/or after tumor resection. There will be be no pain during conscious time. The goal of anesthesia is patient’s comfort, able to stay immobile on OR table during the procedure, and is alert and cooperative to comply with cortical mapping. These goals can be accomplished by 1) adequate preparation of the patients, 2) a comfortable environment, 3) appropriate administration of right analgetic and sedative medication, 4) conduct ongoing communication, 5) perform rapid treatment to any complications. Dexmedetomidine is a highly spesific a-2 adrenoceptor agonist with sedative, analgesic, anesthetic sparring effect, awake if stimulated, brain protection with no addiction effect nor suppress ventilation. Patients treated with dexmedetomidine will be sedated, comfortably but is easily aroused to tolerate a prolonged awake craniotomy.


Keywords


Awake craniotomy; analgesik sedatif; dexmedetomidin; awake craniotomy; analgesic sedative; dexmedetomidine

Full Text:

PDF

References


Bekker AY, Kaufman B, Samir H, Doyle W. The use of dexmedetomidine infusion for awake craniotomy. Anesth Analg 2001;92:1251–3.

Bisri T. Pemakaian dexmedetomidine infus untuk awake craniotomy. Anestesia & Critical Care 2004;22(2):182–89

Manninen P, Contreras J. Anesthetic consideration for craniotomy in awake patients. Int Anesthesiol Clinic 1986;24:157–74.

Blanshard HJ, Chung F, Manninen PH, Taylor MD, Bernstein M. Awake craniotomy for removal of intracranial tumor: considerations for early discharge. Anesth Analg 2001;92:89–94.

Gignac E, Manninen PH, Gelb AW. Comparison of fentanyl, sufentanil and alfentanil during awake craniotomy for epilepsy. Can J Anaesth 1993;40;421–4.

Herrick IA, Craen RA, Gelb AW. Propofol sedation during awake craniotomy for seizure: patient controlled administration versus neurolept analgesia. Anesth Analg 1997;84:285-91.

Johnson KB, Egan TD. Remifentanil and propofol combination for awake craniotomy: case report with pharmacokinetic simulations. J Neurosurg Anesthesiol 1998;10:25-9.

Cotrell JE. Brain protection in neurosurgery: dos and don’ts. ASA Annual Meeting Refresher Course Lecture, October 2002.

Bhana N, Goa KL, Mc Clellan KJ. Dexmedetomidine. Drugs. Adis International 2000;59(2):263–268.

Bloor BC, Ward DS, Belleville JP, Maze M. Effect of intravenous dexmedetomidine in humans, hemodynamic changes. Anesthesiology 1992;77:1134–42.

Villela NR, Nascimento P. Dexmedetomidine in anesthesiology. Rev Bras Anestesiol 2003;53(1):97–113.

Frost EAM. History of neuroanesthesia. Dalam: Albin MS, ed. Textbook of Neuroanesthesia with Neurosurgical and Neuroscience Perspectives. New York: McGraw-Hill; 1997, 1–20

Wan Hassan MN. History of awake craniotomy in hospital Universiti Sains Malaysia. Malays J Med Sci. 2013 Oct; 20(5): 67–69.

Taylor MD, Bernstein M. Awake craniotomy with brain mapping as the routine surgical approach to treating patients with supratentorial intraaxial tumors: a prospective trial of 200 cases. Jour of Neurosurg 1999; 90(1).

Sakabe T, Matsumoto M. Effect of anesthetic agents and other drugs on cerebral blood flow, metabolism, and intracranial pressure. Dalam: Cottrell JE, Young WL, editor. Cottrell and Young’s Neuroanesthesia; 2010, 78–94.

Ohata H, Iida H, Dohi S, Watanabe Y. Intravenous dexmedetomidine inhibits cerebrovascular dilatation induced by isoflurane and sevoflurane in dogs. Anesth Analg 1999;89:370–7.

Zornow MH, Fleisher JE, Scheller MS, Nakakimura K, Drummond JC. Dexmedetomidine, an a2-adrenergic agonist, decreases cerebral blood flow in isoflurane-anesthetized dog. Anesth Analg 1990;70:624–30.

Maninen PH, See JJ. Epilepsy, epilepsi surgery, awake craniotomy for tumor surgery, and intraoperative magnetic resonance imaging. Dalam: Newfield P, Cottrell JE, eds. Handbook of Neuroanesthesia, 4th ed. Philadelphia: Lippincott Williams & Wilkins; 2007, 197–215

Schubert A, Lotto M. Awake craniotomy, eplepsy, minimal invasive, and robotic surgery. Dalam: Cottrell JE, Young WL, eds. Cottrell and Young’s Neuroanesthesia. 5th ed, Philadelphia: Mosby Elsevier; 2010, 296–316




DOI: https://doi.org/10.24244/jni.vol4i3.120

Refbacks

  • There are currently no refbacks.


                                    

 

JNI is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License